医学
银屑病
敌手
药理学
皮肤病科
内科学
受体
作者
Ting‐Shun Wang,Tsen‐Fang Tsai
出处
期刊:Immunotherapy
[Future Medicine]
日期:2019-04-01
卷期号:11 (6): 531-541
被引量:15
标识
DOI:10.2217/imt-2018-0131
摘要
Aim: No guidelines exist for biologic switch in psoriasis after treatment failure. Although, switching between TNF-α antagonists has been reviewed, switching information about newer biologics is limited. Materials & methods: We did a thorough systematic review from ‘PubMed’ and ‘Embase’, which includes new biologics such as IL-12/IL-23 antagonists, IL-17A antagonists and IL-23 antagonists. Results & conclusion: New biologics such as IL-17 antagonist or IL-23 antagonist show greater responses in bio-experienced patients and could even be used for patients in whom previous treatments failed.
科研通智能强力驱动
Strongly Powered by AbleSci AI